Clinical Trial Update: Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia [Phase 3]

View source ↗

Summary

Phase 3 study evaluating mipomersen (ISIS 301012) for homozygous familial hypercholesterolemia has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Mipomersen (mipomersen)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant | Phase 3 | Status: COMPLETED | Results posted: 2013-03-21